University of California
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Budoff, Matthew
T-PLAQUE, NCT05708859: Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Recruiting
4
120
US
Tirzepatide, Mounjaro, Placebo
Matthew J. Budoff, Eli Lilly and Company
Type II Diabetes, Atherosclerosis
12/25
05/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29

Download Options